WO2022130017A3 - Traitement de lymphocytes infiltrant les tumeurs - Google Patents

Traitement de lymphocytes infiltrant les tumeurs Download PDF

Info

Publication number
WO2022130017A3
WO2022130017A3 PCT/IB2021/000883 IB2021000883W WO2022130017A3 WO 2022130017 A3 WO2022130017 A3 WO 2022130017A3 IB 2021000883 W IB2021000883 W IB 2021000883W WO 2022130017 A3 WO2022130017 A3 WO 2022130017A3
Authority
WO
WIPO (PCT)
Prior art keywords
tils
infiltrating lymphocytes
tumor infiltrating
processing
methods
Prior art date
Application number
PCT/IB2021/000883
Other languages
English (en)
Other versions
WO2022130017A2 (fr
Inventor
Ryan Guest
Joanne MCCAFFREY
John LEGALL
Zachary Roberts
Original Assignee
Instil Bio (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instil Bio (Uk) Limited filed Critical Instil Bio (Uk) Limited
Priority to EP21865325.1A priority Critical patent/EP4263808A2/fr
Priority to AU2021404204A priority patent/AU2021404204A1/en
Priority to CA3205464A priority patent/CA3205464A1/fr
Priority to JP2023536944A priority patent/JP2023554425A/ja
Publication of WO2022130017A2 publication Critical patent/WO2022130017A2/fr
Publication of WO2022130017A3 publication Critical patent/WO2022130017A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C12N2500/62—DMSO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des méthodes d'isolement et de cryoconservation de lymphocytes infiltrant les tumeurs (TIL) et de production de populations thérapeutiques de TIL, comprenant des méthodes par l'utilisation d'un kit et d'un dispositif semi-automatique pour la désagrégation, l'enrichissement et la cryoconservation aseptiques d'une tumeur réséquée avant l'expansion de la population TIL. La présente invention concerne également des méthodes d'expansion et/ou de stabilisation de TIL, par exemple des UTIL, des compositions les comprenant et des méthodes de traitement les mettant en jeu.
PCT/IB2021/000883 2020-12-18 2021-12-16 Traitement de lymphocytes infiltrant les tumeurs WO2022130017A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP21865325.1A EP4263808A2 (fr) 2020-12-18 2021-12-16 Traitement de lymphocytes infiltrant les tumeurs
AU2021404204A AU2021404204A1 (en) 2020-12-18 2021-12-16 Processing of tumor infiltrating lymphocytes
CA3205464A CA3205464A1 (fr) 2020-12-18 2021-12-16 Traitement de lymphocytes infiltrant les tumeurs
JP2023536944A JP2023554425A (ja) 2020-12-18 2021-12-16 腫瘍浸潤リンパ球の処理

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063127639P 2020-12-18 2020-12-18
US202063127582P 2020-12-18 2020-12-18
US63/127,582 2020-12-18
US63/127,639 2020-12-18
US202163288409P 2021-12-10 2021-12-10
US202163288414P 2021-12-10 2021-12-10
US63/288,409 2021-12-10
US63/288,414 2021-12-10

Publications (2)

Publication Number Publication Date
WO2022130017A2 WO2022130017A2 (fr) 2022-06-23
WO2022130017A3 true WO2022130017A3 (fr) 2022-07-28

Family

ID=80628849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/000883 WO2022130017A2 (fr) 2020-12-18 2021-12-16 Traitement de lymphocytes infiltrant les tumeurs

Country Status (5)

Country Link
EP (1) EP4263808A2 (fr)
JP (1) JP2023554425A (fr)
AU (1) AU2021404204A1 (fr)
CA (1) CA3205464A1 (fr)
WO (1) WO2022130017A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190070222A1 (en) * 2017-03-29 2019-03-07 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019190579A1 (fr) * 2018-03-29 2019-10-03 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
WO2019210131A1 (fr) * 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
DK1895010T3 (da) 1997-12-22 2011-11-21 Oxford Biomedica Ltd Vektorer baseret på virus for infektiøs hesteanæmi (eiav)
EP2316490A3 (fr) 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Methodes et compositions pour améliorer l'administration de molécules bioactives
HUE054318T2 (hu) 2010-11-12 2021-08-30 Nektar Therapeutics IL-2 molekularész konjugátumai és polimer
RU2671897C2 (ru) 2013-03-01 2018-11-07 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
JP7413639B2 (ja) 2014-06-11 2024-01-16 ポリバイオセプト ゲーエムベーハー 能動的細胞免疫療法のためのサイトカイン組成物を用いたリンパ球の増殖
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
GB201801067D0 (en) 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
GB201810181D0 (en) 2018-06-21 2018-08-08 Immetacyte Ltd Cells expressing chimeric recominant growth factor receptors
GB201900858D0 (en) 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
JP2022522793A (ja) 2019-03-01 2022-04-20 アシンプトート リミテッド 閉じた組織分離および冷凍保存
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190070222A1 (en) * 2017-03-29 2019-03-07 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019190579A1 (fr) * 2018-03-29 2019-10-03 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
WO2019210131A1 (fr) * 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAFNI U ET AL: "Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis", ANNALS OF ONCOLOGY, vol. 30, no. 12, 1 December 2019 (2019-12-01), NL, pages 1902 - 1913, XP055917820, ISSN: 0923-7534, Retrieved from the Internet <URL:https://dul.usage.elsevier.com/doi/> DOI: 10.1093/annonc/mdz398 *
GASTMAN BRIAN ET AL: "DELTA-1: A global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. Suppl 2, 1 November 2021 (2021-11-01), pages A573 - A573, XP055917785, Retrieved from the Internet <URL:https://jitc.bmj.com/content/jitc/9/Suppl_2/A573.full.pdf> DOI: 10.1136/jitc-2021-SITC2021.544 *
LINH T. NGUYEN ET AL: "Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)", PLOS ONE, vol. 5, no. 11, 10 November 2010 (2010-11-10), pages e13940, XP055742005, DOI: 10.1371/journal.pone.0013940 *
MARCO DONIA ET AL: "Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor", CYTOTHERAPY, vol. 16, no. 8, 1 August 2014 (2014-08-01), GB, pages 1117 - 1120, XP055296812, ISSN: 1465-3249, DOI: 10.1016/j.jcyt.2014.02.004 *

Also Published As

Publication number Publication date
JP2023554425A (ja) 2023-12-27
WO2022130017A2 (fr) 2022-06-23
EP4263808A2 (fr) 2023-10-25
AU2021404204A1 (en) 2023-07-06
CA3205464A1 (fr) 2022-06-23

Similar Documents

Publication Publication Date Title
MX2022007598A (es) Dispositivos y métodos para el aislamiento de linfocitos infiltrantes de tumores y usos de los mismos.
WO2022130017A3 (fr) Traitement de lymphocytes infiltrant les tumeurs
Donnez et al. Ovarian cortex transplantation: time to move on from experimental studies to open clinical application
WO2022130015A3 (fr) Traitement de lymphocytes infiltrant les tumeurs
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2002051439A3 (fr) Compositions et procedes destines au traitement et a la prevention de troubles et de maladies cardio-vasculaires, et a l&#39;identification d&#39;agents therapeutiques correspondants
CA3155727A1 (fr) Edition genique de lymphocytes infiltrant les tumeurs et leurs utilisations en immunotherapie
HUP0203920A2 (hu) Eljárás szelektált spermasejtek mélyhűtésére
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn&#39;s
WO2004071283A3 (fr) Utilisation de sang de cordon ombilical pour traiter des individus presentant une maladie, un trouble ou une pathologie
WO2003084539A3 (fr) Nouvelles compositions pharmaceutiques a base d&#39;anticholinergiques et d&#39;inhibiteurs de la kinase p38
SG155053A1 (en) Method of obtaining viable human liver cells, including hepatic stem/progenitor cells
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
MX336500B (es) Insecticida para uso agricola u horticola y metodo para su uso.
WO2003099771A3 (fr) Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
WO2005041656A3 (fr) Procedes, compositions et dispositifs pour induire une stase dans des tissus et des organes
MXPA05004247A (es) Cromonas y derivados de cromona y usos de los mismos.
WO2004031129A3 (fr) Nouveaux composes destines au traitement des maladies auto-immunes, des maladies immuno-allergiques et des rejets en cas de greffes d&#39;organes ou de tissus
WO2006060309A3 (fr) Compositions et procedes de preservation d&#39;organes ex vivo
WO2004030622A3 (fr) Methodes d&#39;isolement et d&#39;auto-assemblage de petites particules proteiniques presentes dans du sang ou dans d&#39;autres matieres biologiques
MXPA03005477A (es) Concentrados de sabor.
WO2002091858A8 (fr) Compositions anxiolytiques de marcgraviaceae contenant de l&#39;acide betulinique ou des derives d&#39;acide betulinique et procedes associes

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3205464

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2023536944

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2021404204

Country of ref document: AU

Date of ref document: 20211216

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021865325

Country of ref document: EP

Effective date: 20230718

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21865325

Country of ref document: EP

Kind code of ref document: A2